REG - Convatec Group PLC - AGM Trading Update

ConvaTecAnnouncement

16/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240516:nRSP6289Oa&default-theme=true

RNS Number : 6289O  Convatec Group PLC  16 May 2024

16 May 2024

 

Revenue continued to build, further strategic progress, on track to deliver
financial guidance

Convatec Group Plc ("Convatec" or the "Group"), a global medical products and
technologies company, announces its trading update for the four months ended
30 April 2024. Group revenue increased by 5.2% on a reported basis, 5.4% on a
constant currency basis and 6.5% on an organic basis(1).  The Group remains
confident of delivering its full year guidance as set out below.

Broad-based growth across all four categories

In Advanced Wound Care, organic revenue growth for the first four months was
mid-single digit as expected. The performance in the US was strong, with good
growth across the portfolio enhanced by InnovaMatrix(®). In Europe and Global
Emerging Markets growth was good, despite some continuing impact of the
Chinese market-wide anti-bribery and corruption campaign.

In Ostomy Care, organic revenue growth was mid-single digit as expected. There
was good growth in Europe, supported by the strong response to the Esteem Body
launch in Italy, and in Global Emerging Markets growth was strong. The
positive performance in North America was supported by new patient referrals
to the Home Services Group.

In Continence Care, organic revenue growth was high-single digit, higher than
expected, with strong new patient starts and a further increase in
reimbursement levels in US. Although small, the performance in Europe and
Global Emerging Markets was supportive of growth with an encouraging customer
response to our new launch of GentleCath(TM) Air for Women in France.

In Infusion Care, organic revenue growth was mid-single digit as expected,
with phasing of growth weighted to the second half based on continuing strong
underlying demand for Convatec's infusion sets both within and outside of
diabetes. Diversification of products and customers is progressing well.

Continued strategic progress

·    New product innovation progressing well

·    In Advanced Wound Care: the win-rate for ConvaFoam(TM) evaluations in
the US remains strong. The regulatory clearance process for Europe is on track
with launches planned for later this year

·    In Ostomy Care: Esteem Body(TM) launched in Italy in March to a
strong response. We have also started launching in the US, Czech Republic and
Poland

·    In Continence Care: demand for GentleCath(TM) Air for Women continued
to build following the launch in France in Q4 last year, and is expected to
launch in other key European markets and the US later this year

·    In Infusion Care: recent new launch activity in diabetes is yielding
strong demand for our innovative infusion sets with Tandem's Mobi, Beta
Bionics' iLet, Ypsomed's YpsoPump and Medtronic's 780G insulin pumps. Outside
of diabetes, the roll out of AbbVie's Parkinson's pump therapy is progressing
well in Japan and key European countries leading to strong demand for
Convatec's Neria(TM) guard infusion sets. AbbVie expects to launch in the US
later this year

 

·    Clinical evidence capability delivering

·    The company continues to invest in and strengthen its clinical
evidence generation and dissemination capability to support the use of its
solutions - new team leaders embedded for each of the categories

·    For AQUACEL(®) Ag+ Extra™ in May, we announced preliminary
clinical study results from a multinational randomised controlled trial (RCT).
The study found that venous leg ulcers managed with AQUACEL(®) Ag+ Extra™
were 31% more likely to heal completely at 12 weeks and 31% more likely to
have a 40% reduction in wound area at 4 weeks, compared with the standard of
care dressing

·    For InnovaMatrix(®) two prospective clinical studies are underway in
the US for Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU) which are
expected to complete and be published later this year. In addition, the
results of two Real World Evidence studies are expected to be published later
this year

 

 

Response to draft proposed local coverage determinations (LCD)

Convatec notes the proposed draft LCDs relating to skin substitutes for DFU
and VLU for the advanced wound care biologics segment, published on 25(th)
April. We are actively engaging with all relevant parties during the 45-day
consultation window, which may lead to different outcomes than the current
draft proposal. Convatec firmly believes that InnovaMatrix(®) delivers strong
clinical outcomes for patients and choice for health care practitioners. See
notes below for further detail.

 

Reiterating guidance - FY 2024 and medium-term

The Group is on track to deliver on its guidance for 2024:

·    Organic revenue growth between 5.0% and 7.0%

·      Advanced Wound Care: growth reduced to mid to high-single digit,
recognising short-term uncertainty from the draft proposed LCDs

·      Ostomy Care: mid-single digit growth, remains unchanged

·      Continence Care: growth increased to mid to high-single digit,
given the more positive performance and outlook

·      Infusion Care: high-single digit growth, remains unchanged

·    Adjusted operating profit margin on a constant currency basis of at
least 21.0% (FY2023: 20.2%)

·    Double digit growth in adjusted EPS and free cash flow to equity

 

Medium term guidance remains unchanged:

The breadth of Convatec's portfolio and strong underlying demand in its
chronic care segments, coupled with its innovative new product pipeline, gives
management confidence in the medium-term prospects for the Group. Convatec
continues to expect to deliver 5-7% organic revenue growth annually, to expand
the adjusted operating margin to mid-20s by 2026 or 2027 and to deliver double
digit compound annual growth in adjusted EPS and free cash flow to equity
going forward.

 

***

Conference call details

 

A conference call to discuss the trading update will be held for analysts and
investors at 08:00hrs UK time. Please register using this link.
(https://convatec-agm-trading-update-2024.open-exchange.net/registration)

 

Footnotes

 

1 Organic growth is calculated by applying the applicable prior period average
exchange rates to the Group's actual performance in the respective period and
excluding acquired and disposed/discontinued businesses. For the first four
months of 2024 this relates to adjustments for the residual critical care
revenues in 2023 and the small Continence Care acquisitions

2 Our fecal management system product portfolio

 

 

 

 

Contacts

 Analysts & Investors      Kate Postans,                                       +44 (0) 7826 447807

Vice President, Investor Relations & Treasury
                           Sheebani Chothani,                                  +44 (0) 7805 011046

Director, Investor Relations

                                                                               ir@convatec.com (mailto:ir@convatec.com)
 Media                     Buchanan: Charles Ryland / Chris Lane               +44 (0)207 466 5000

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in advanced
wound care, ostomy care, continence care, and infusion care. With around
10,000 colleagues, we provide our products and services in almost 100
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Group revenues in 2023
were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more about Convatec, please visit
http://www.convatecgroup.com (http://www.convatecgroup.com)

 

 

About InnovaMatrix(®) and the draft LCD proposal

Following 510(k) FDA clearance, InnovaMatrix(®) launched in the US in early
2022 as the first porcine placental-derived extra cellular matrix device. The
InnovaMatrix(®) products are cleared for use by the FDA for the management of
wounds including pressure ulcers, diabetic foot ulcers, venuous leg ulcers,
chronic vascular ulcers, surgical wounds (including post-Mohs surgery),
partial/full-thickness wounds and trauma wounds. In 2023 revenue from
InnovaMatrix(®) products was $74 million, equating to just over 3% of
Convatec's Group revenue.

Since launching InnovaMatrix(®), Convatec has been generating clinical
evidence. Clinicians and patients have experienced first-hand the positive
impact InnovaMatrix(®) products have on chronic wounds. The Group is
confident in the clinical efficacy of its innovative porcine xenograft
platform and has four clinical studies underway in the US (prospective
clinical DFU study, prospective clinical VLU study and two Real World Evidence
studies) which are expected to be published later this year.

On 25 April 2024, seven Medicare Administrative Contractors (MACs) published
draft proposed LCDs relating to use of products to treat Diabetic Foot Ulcers
(DFU) and Venous Leg Ulcers (VLU). While our InnovaMatrix(®) product meets
the technical requirements of the draft proposed LCD, its recent entry to the
market and the timeline necessary to generate and to publish clinical evidence
means InnovaMatrix is not currently on the draft proposed covered list.

Convatec is actively engaging with all relevant parties as part of the 45-day
consultation process currently underway. We are seeking an outcome that
preserves choice for clinicians treating chronic wounds, ensures access to
innovative, effective products which are in the best interest of patients and
maintains the benefits of the well-proven 510(k) pathway for fostering
innovation of new products for the benefit of patients.

 

Forward Looking Statements

This document includes certain forward-looking statements with respect to the
operations, performance and financial condition of the Group. Forward-looking
statements are generally identified by the use of terms such as "believes",
"estimates", "aims", "anticipates", "expects", "intends", "plans", "predicts",
"may", "will", "could", "targets", continues", or their negatives or other
similar expressions. These forward-looking statements include all matters that
are not historical facts.

Forward-looking statements are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by the Company, are
inherently subject to significant business, economic and competitive
uncertainties and contingencies that are difficult to predict and many of
which are outside the Group's control. As such, no assurance can be given that
such future results, including guidance provided by the Group, will be
achieved. Forward-looking statements are not guarantees of future performance
and such uncertainties and contingencies, including the factors set out in the
"Principal Risks" section of the Strategic Report in our Annual Report and
Accounts, could cause the actual results of operations, financial condition
and liquidity, and the development of the industry in which the Group
operates, to differ materially from the position expressed or implied in the
forward-looking statements set out in this document. Past performance of the
Group cannot be relied on as a guide to future performance.

Forward-looking statements are based only on knowledge and information
available to the Group at the date of preparation of this document and speak
only as at the date of this document. The Group and its directors, officers,
employees, agents, affiliates and advisers expressly disclaim any obligations
to update any forward-looking statements (except to the extent required by
applicable law or regulation).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBCGDUXBBDGSU